ASCO 2021
Virtual Scientific Program

June 4-8

Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021

Read the Press Release

New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score® Test in Node-Positive Early-Stage Breast Cancer

Read the Press Release

Cancer is detected too late.
Exact Sciences is changing the way we think about detecting and treating cancer. As a global leader in cancer testing, we are committed to providing earlier answers and life-changing treatment guidance.

Supporting Patients at Every Stage

Exact Sciences’ portfolio of products primarily focuses on colorectal, breast and prostate cancers, with research and development looking at the top 15 deadliest cancers including multi-cancer testing.

Our vision is to eradicate cancer and the suffering it causes through tests that detect it earlier and provide guidance for successful treatment.

Prognosis / Therapy Selection
Minimal Residual Disease
Recurrence Monitoring
Therapy Selection

Finding Cancer at its Earliest Stages

When found early, cancer is often more effectively treated, enabling better outcomes for patients. Our goal is to integrate a blood test to screen for multiple types of cancer into routine medical care.

Cologuard® is an easy, effective, non-invasive colorectal cancer screening test for average risk adults 45 and older. Cologuard can be used at home and finds 92% of cancers overall and 94% of Stage I and Stage II cancers.

Making cancer care smart with genomic tests

Every cancer is unique and affects each diagnosed person differently based on the individual biology of their disease. To address this diversity and make cancer care smart at every stage, our Oncotype DX® and Oncotype MAP™ tests deliver clinically relevant genomic intelligence that reveals the individual biology of a patient's tumor.

oncotypeiq.comLearn more about our portfolio

Virtual ABSTRACTS of Interest

Impact of the Sessile Serrated Polyp Pathway on Predicted Colorectal Cancer Outcomes in the CRC-AIM Model

Authors: Kisiel, J., et al.

Session: Prevention, Risk Reduction, and Hereditary Cancer

Abstract Number: 10545

Learn More

Cancer screening utilization in patients diagnosed with cancer types with and without recommended screening modalities

Authors: Cohain, A., et al

Session: Prevention, Risk Reduction, and Hereditary Cancer

Abstract Number: 10557

Learn More

Utilizing commercial health insurance claims data to identify the impact of cancer screening and estimate the added benefit of a multi-cancer liquid biopsy ordered during routine physical exams

Authors: Cohain, A., Hathaway, C., et al.

Session: Publication Only – Prevention, Risk Reduction, and Hereditary Cancer

Abstract Number: e22516

Learn More

Cost-effectiveness of Oncotype DX Breast Recurrence Score test in postmenopausal women with node-positive early breast cancer based on the RxPONDER trial

Authors: Berdunov, V., et al.

Session: Breast Cancer – Local/Regional/Adjuvant

Abstract Number: 534

Learn More

Prognostic impact of Recurrence Score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial

Authors: Gluz, O., et. al

Session: Breast Cancer – Local/Regional/Adjuvant

Abstract Number: 504; Oral presentation on June 6, 2021 at 8 AM EDT.

Learn More

Discovery and validation of a genomic signature to identify women with early-stage invasive breast cancer who may safely omit adjuvant radiotherapy after breast-conserving surgery

Authors: Sjöström, M., et al.

Session: Breast Cancer –Local/Regional/Adjuvant

Abstract Number: 512

Learn More

Patient-specific meta-analysis of 3 validation studies of the 12-gene Colon Cancer Recurrence Score Assay for recurrence risk assessment after surgery with or without 5FU and oxaliplatin.

Authors: Yothers, G., et al.

Session: Gastrointestinal Cancer –
Colorectal and Anal

Abstract Number: 3599

Learn More


Authors: Gray, S., et al

Session: Prevention, Risk Reduction, and Hereditary Cancer

Abstract Number: 10603

Learn More